New Progress in the Relationship between Immune Cells, PD-1 in Tumor Microenvironment and the Efficacy of EGFR-TKIs
10.3779/j.issn.1009-3419.2017.11.09
- VernacularTitle:肿瘤微环境内的免疫细胞、PD-1与EGFR-TKIs疗效关系新进展
- Author:
YUAN SHIYANG
1
;
XU HUI
;
XIE JUNPING
Author Information
1. 南昌大学第二附属医院呼吸与危重症医学科
- Keywords:
Tumor microenvironment;
Lung neoplasms;
Targeted therapy;
Immune cells;
EGFR-TKIs;
Pro-gramed cell death protein 1
- From:
Chinese Journal of Lung Cancer
2017;20(11):775-780
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, targeted therapy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) is the leading treatment modality for patients with advanced non-small cell lung cancer (NSCLC) and EGFR gene muta-tion. However, with the prolongation of the medication time, most of the patients appeared drug resistance. Tumor microenvi-ronment is the internal environment for the survival and development of tumor cells. The immune response which mediated by immune cells, like regulatory T (Treg), dendritic cells, macrophages, fibroblasts, etc. And the programmed cell death receptor 1 (PD-1) with its ligand PD-1L/PD-2L may participate in the drug resistance of EGFR-TKIs. This review will elaborate the possible mechanism of the interaction of immune cells on EGFR-TKIs in the tumor microenvironment, in order to seek new targets, and further improve the anti-tumor e?cacy and prolong the effective time of EGFR-TKIs.
